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In accordance with our hypothesis the 12 patients' leptin levels prior to initiation of clozapine treatment Keywords: body weight regulation; neuroleptics; cytokines; differed significantly from levels measured afterwards overeating; binge-eating; weight gain (relative increases at week 1 Ͻ35%). None of these clozapine were sufficient to induce this effect. Within a three patients had a relative increase at any time point 10-week period mean body weight, mean body mass index, mean fat mass and mean lean body mass all in excess of 55% despite the fact that they received increased. Based on the results we suggest that in prehigh maximal daily doses of clozapine (600-disposed individuals clozapine induces an increased 900 mg day −1 ).
appetite; overeating and weight gain can ensue, which
The four patients in whom clozapine treatment was in turn underlie elevated leptin secretion.
intermittently discontinued deserve special considerWeight gain is a relevant side-effect of treatment with ation. At week 1 three of these patients had relative the atypical neuroleptic drug clozapine.
1-6 Weight gain increases of their leptin levels of 109%, 198% and under clozapine apparently exceeds that observed 318%, respectively, while the fourth patient had a upon use of typical neuroleptics. 7, 8 The mechanisms decrease of 15%. Upon discontinuation of clozapine, are poorly understood, but some hypotheses have been leptin levels of all patients dropped to or below basesuggested. 9 Patients frequently report an inability to line. After treatment was reinitiated leptin levels again suppress appetite after a full meal, suggesting a change increased in only those three patients who had already in satiety perception. 3 An increase in appetite and shown the initial increase. carbohydrate craving have also been reported. 10 In Statistical analyses revealed that the patients' mean some studies weight gain has been associated with a body weight, mean BMI, mean fat mass and mean lean positive psychopathological outcome. 3, 6 Clozapine body mass increased during the observation span (all binds with different affinities to diverse serotonin nominal P-values Ͻ0.01; Table 1 ). The net differences receptors and dopamine receptors. Binding also occurs in weight, BMI, and fat mass between baseline and to histamine, muscarinic and alpha-adrenergic recepweeks 1 and 2, respectively, revealed correlations tors. 11 Accordingly, one or more of these neurobetween 0.3 and 0.75 to the relative increases in serum transmitter systems are presumably involved in the leptin levels at weeks 1 and 2 (Table 2) . Correlation weight gain related to clozapine.
coefficients between these increases and lean body mass were negative. Leptin is a hormone synthesized by adipocytes.
12,13
Figure 1 Mean relative increases of serum leptin levels in 12 patients during treatment with clozapine in relation to the baseline (pretreatment) level (bars indicate 95% confidence intervals). A single patient each was not available for blood sampling at weeks 1 and 2. The four patients in whom clozapine treatment was intermittently discontinued at week 3 or 4 were subsequently excluded. All P-values (two-sided non-randomized Wilcoxon-test) are nominal. Bioelectrical impedance analyses were carried out in nine patients (*). Within the 10-week observation period, mean body weight, mean body mass index, mean fat mass and mean lean body mass increased (all nominal P-values Ͻ 0.01).
Nine of the 12 patients reported an increased appetite criteria for binge-eating disorder. The binge-eating commenced within the first week of treatment. In one of the and/or hunger. These patients reported an increased desire for sweets and soft drinks (n = 7), salty crackers two patients these episodes ceased upon intermittent discontinuation of clozapine treatment and recommenced (n = 1) or sandwiches (n = 1). Two patients developed binge-eating episodes as specified in the DSM-IV research after reinitiation. Both patients gained weight rapidly.
12 patients (Figure 1 ). Small doses of the drug are leptin levels and weight or fat mass gain (Table 2) support this interpretation. In order to test whether the rise is indeed only due to overeating and subsequent gain A single patient without an increase in leptin levels and who gained 3 kg (as fat-free mass only) during the in fat mass, we would have had to precisely control the food intake of the patients and have a group of controls, observation span did not report an alteration of his hunger sensation. It was not possible to reliably delinmatched for BMI and percent body fat, also raise their energy intake by a similar percentage. Even then direct eate any alterations of hunger sensations in the two other patients (weight gains of 0 and 1.1 kg over the comparisons would presumably be rendered difficult by individual variation of the leptin response to over-10-week period), whose leptin levels also remained within the baseline range throughout the observation eating and weight gain. Increased leptin secretion might signal the attempt of period.
Pretreatment did not seem to have an effect on the the organism to counter-regulate the increased energy intake through an increase in energy expenditure. As clozapine-induced increase in leptin secretion because all three non-pretreated patients showed the initial long as the effects of clozapine on energy intake override the counterregulation, the energy balance is posiincrease at weeks 1 and 2. All of the four patients who received no co-medication during the observation span tive and as a result weight gain ensues until energy intake and expenditure reach a new balance. We can-(mean weight gain: 5.15 kg) showed the initial leptin increase; this group included the patient with the highnot exclude that another mechanism -alternative to or in addition to the effect brought about by an increased est weight gain during the observation span (8.2 kg).
Statistical analyses also revealed that the initial energy intake -is involved in the up-regulation of leptin. increase in relative leptin levels at week 1 or 2 was seemingly not strongly related to mean daily doses of Interestingly, clozapine increases the plasma levels of tumor necrosis factor-␣, soluble TNF receptors p55 clozapine or to serum levels of clozapine and its metabolites (all correlation coefficients Ͻ0.4). Even the and p75, and interleukin-2. 22 Weight changes were not reported in that study. Leptin itself is related in strucpatient with the lowest dose (50 mg day −1 throughout the whole observation period) showed an increase of ture to the family of helical cytokines. 23, 24 In conclusion, despite some limitations of this study circulating leptin levels at week 1.
The major finding of this study is that leptin including the small case number, the lack of a washout phase, co-medication in some patients and the lack secretion is altered upon initiation of clozapine treatment in a substantial proportion of patients. In our of an adequate control group and of a standardised protocol for the assessment of the patients' eating study group secretion increased rapidly in eight out of behavior, we have clearly shown that clozapine can determined with a sensitive radioimmunoassay; 27 serum levels of clozapine and its metabolites were alter leptin secretion. In individual patients serum leptin levels increase more than five-fold over baseline. measured with high performance liquid chromatography. 28 Based on our data we assume that this increase is related to overeating and subsequent weight gain During clozapine treatment ten patients were questioned as to alterations of their energy intake and of induced by clozapine. The implications of these findings for the effects of clozapine on energy intake, their eating behavior using a semi-structured questionnaire on a weekly basis. Two patients were not able to weight regulation and psychopathology merit further consideration.
adequately reflect their eating behavior.
Statistical analyses Sample and methods
Our hypothesis was that leptin secretion is altered by This prospective study assessed body mass index (BMI; initiation of clozapine treatment. We investigated this kg m −2 ), body composition, serum leptin levels, serum hypothesis under the assumption of normally distriblevels of clozapine and of two metabolites in 12 conuted relative serum leptin levels. Detailed formulas of secutively ascertained psychiatric inpatients before the applied linear model and the robust Wald statistic and after initiation of treatment with clozapine. These are given by Arminger 29 (p 127, Eqns (3.231), (3.234) six males and six females had diagnoses of schizoand (3.237)). All other statistical analyses were of an phrenia (n = 9) or schizoaffective disorder (n = 3) exploratory nature. All calculations were performed according to the DSM-IV criteria 25 with a variety of with the statistical software package STATISTICA for subtypes. Mean age (± s.d.) of the total group was Windows 5.0. 31 ± 7.1 (range 22-44) years. All 12 patients gave writ-
The four patients in whom clozapine treatment was ten informed consent; the study was approved by the intermittently discontinued in weeks 3 or 4 were subEthics Committee of the University of Marburg. sequently excluded from the weekly calculations of the Eleven patients were followed-up for 10 weeks upon mean relative increase in serum leptin levels over baseinitiation of treatment with clozapine; one patient was line (Figure 1 ). The relative increases in mean leptin discharged in week 7. During the observation period levels at weeks 1-10 in relation to baseline were (70 days), clozapine therapy was intermittently disconexploratorily assessed with a two-sided non-rantinued in four patients in the third or fourth week of domized Wilcoxon-test (Figure 1 ). All patients excludtreatment for 6, 7, 11 and 26 days, respectively, due to ing the patient who was discharged at week 7 were serious side-effects including fever and diarrhea (n = 3) included in the descriptive analysis of the relevant and binge-eating episodes associated with rapid weight anthropometric data at baseline and weeks 1, 2 and 10 gain (n = 1).
( Table 1 ). Pearson's correlation coefficients were used In 11 patients clozapine dosage was raised gradually to descriptively assess the influence of the anthropoduring the first treatment stage and subsequently metric variables (Table 2 ) and of the mean daily doses adjusted to clinical requirements; the mean clozapine of clozapine, serum levels of clozapine and its metabdose (± s.d.) was 273 ± 142.3 (range 81-475) mg day
olites on leptin secretion. One patient received 50 mg day −1 throughout the 70 days. Acknowledgements Nine patients had been pretreated with diverse neuroleptics and/or other psychopharmacologically active We are indebted to the patients who participated in drugs directly prior to initiation of clozapine treatment.
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All patients were blood sampled on the day preceding initiation of clozapine treatment (baseline: week 0) References and subsequently on a weekly basis for up to 10 weeks. 
